SATELLOS BIOSCIENCE INC (MSCL.CA) Stock Price & Overview
TSX-V:MSCL • CA80401L8033
Current stock price
The current stock price of MSCL.CA is 8.61 CAD. Today MSCL.CA is down by -10.31%. In the past month the price decreased by -49.38%. In the past year, price decreased by -10.31%.
MSCL.CA Key Statistics
- Market Cap
- 863.945M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
MSCL.CA Stock Performance
MSCL.CA Stock Chart
MSCL.CA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MSCL.CA. When comparing the yearly performance of all stocks, MSCL.CA is a bad performer in the overall market: 71.29% of all stocks are doing better.
MSCL.CA Earnings
MSCL.CA Forecast & Estimates
MSCL.CA Groups
Sector & Classification
MSCL.CA Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MSCL.CA Ownership
MSCL.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 554.41M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 418.361M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 140.539M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 52.555M | ||
| COV | COVALON TECHNOLOGIES LTD | 11.93 | 47.506M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 37.483M | ||
| RVX | RESVERLOGIX CORP | N/A | 34.751M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 3.25 | 31.867M | ||
| HEM | HEMOSTEMIX INC | N/A | 12.691M | ||
| MPH | MEDICURE INC | N/A | 11.693M | ||
| KNE | KANE BIOTECH INC | N/A | 5.448M | ||
| QPT | QUEST PHARMATECH INC | N/A | 5.074M | ||
| TELO | TELO GENOMICS CORP | N/A | 4.519M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the TSX Venture Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About MSCL.CA
Company Profile
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. The company is headquartered in Toronto, Ontario and currently employs 3 full-time employees. The company went IPO on 2006-12-01. The firm is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1.
Company Info
IPO: 2006-12-01
SATELLOS BIOSCIENCE INC
79 Wellington Street West, 33rd Floor
TORONTO ONTARIO CA
Employees: 3
Phone: 16476601780
SATELLOS BIOSCIENCE INC / MSCL.CA FAQ
What does SATELLOS BIOSCIENCE INC do?
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. The company is headquartered in Toronto, Ontario and currently employs 3 full-time employees. The company went IPO on 2006-12-01. The firm is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1.
Can you provide the latest stock price for SATELLOS BIOSCIENCE INC?
The current stock price of MSCL.CA is 8.61 CAD. The price decreased by -10.31% in the last trading session.
Does SATELLOS BIOSCIENCE INC pay dividends?
MSCL.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of MSCL stock?
MSCL.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the number of employees for SATELLOS BIOSCIENCE INC?
SATELLOS BIOSCIENCE INC (MSCL.CA) currently has 3 employees.
Who owns SATELLOS BIOSCIENCE INC?
You can find the ownership structure of SATELLOS BIOSCIENCE INC (MSCL.CA) on the Ownership tab.